Skip to content

Inspection Record

Microvascular Tissue, Inc — FDA 483 Findings

US FDAInspected 2025-04-08Published 2026-10-26 4 findingsComplaint and recall handlingProcess validationMaterial and supplier control

Inspectors Garrad R Poole · Richard T RiggieThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Complaint and recall handling

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

2Process validation

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

3Material and supplier control

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests ifthey exist.

4Material and supplier control

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Microvascular Tissue, Inc company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.